ArticleScientific reports2024
The potential inhibitory mechanism of EGCG against the Chikungunya virus targeting non-structural protein 2 through molecular dynamics simulation.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Recent progress in anti-Chikungunya virus drug discovery: Focus on the viral life cycle and direct-acting antivirals.Virologica Sinica · 2026Review
- Emetine dihydrochloride inhibits Chikungunya virus nsP2 helicase and shows robust antiviral activity in cells and mice.Journal of biomedical science · 2026Article
- Recent advances in antiviral drugs for Chikungunya virus (CHIKV): Targets, mechanisms, and development strategies.Acta pharmaceutica Sinica. B · 2026Review
- Recent Insights into Protein-Polyphenol Complexes: Molecular Mechanisms, Processing Technologies, Synergistic Bioactivities, and Food Applications.Molecules (Basel, Switzerland) · 2026Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
This study explores the potential of Indonesian herbal compounds against the chikungunya virus (CHIKV), which causes widespread illness without a specific cure known as chikungunya fever (CHIKF). By focusing on the nsP2 protein, crucial for the virus's replication, the research utilizes computational methods identifying inhibitor compounds with high binding affinity. These promising candidates are further analyzed through 1 µs of molecular dynamic (MD) simulation studies, aiming to find effective inhibitors to control the chikungunya spread, leveraging Indonesia's rich biodiversity for novel anti-CHIKV therapies. The results of our study highlight the molecular mechanism of the potential of epigallocatechin 3-O-gallate (EGCG) from Camelia sinensis in inhibiting nsP2 protease by binding to essential catalytic residues and exploring more energetically favorable orientations within the catalytic pocket. This dynamic binding process suggests that EGCG may disrupt the protease's catalytic functions, potentially altering domain interactions without compromising the protein's overall structure. Given nsP2's minimal homology with human proteins, the risk of cross-reactivity is reduced, making it a suitable target for CHIKV therapy. This study suggests EGCG as a prime candidate for further development as a broad-spectrum inhibitor against CHIKF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.